Ipsen to acquire Memo Therapeutics and its kidney infection candidate

French drugmaker Ipsen announced a new acquisition, agreeing to buy Memo Therapeutics along with its experimental kidney infection drug. This marks Ipsen's second transaction announced within a week, underscoring an active M&A strategy.

The deal brings Memo's lead candidate, potravitug, into Ipsen's pipeline, potentially expanding its portfolio in infectious disease treatments. Details on the transaction value were not disclosed in the announcement.

Industry observers note that the acquisition could strengthen Ipsen's position in the renal infection market, though the drug remains in early development stages. The move reflects broader consolidation trends in the pharmaceutical sector as companies seek to diversify and bolster their pipelines.